• InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for transcarotid artery revascularization procedures.
• The approval doubles the platform's U.S. addressable market, adding access to more than 35,000 procedures annually, according to company estimates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121601PRIMZONEFULLFEED1001303345) on November 12, 2026, and is solely responsible for the information contained therein.